Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: arnie h who wrote (879)	8/22/1999 8:46:00 AM
From: David Lindblade	Read Replies (2) \| Respond to of 1386

80 M shares? They can't be serious about actually doing that can they? Isn't this merely a negotiating tactic - showing big and medium pharma and Carl Icahn et al that they can do it themselves if they want to, so pony up now or we'll go it alone. If they go ahead and dilute to 80M the share price will tank IMO . . . unless they time it with outstanding news of some sort. Even then, news about future potential for HU211 which is several years off in the best case hasn't influenced PARS to this point; and, positive impact from the eye drug revenue will be cut in half due to dilution. Tell me this is a negotiating tactic, PLEASE. I'm in this for the long haul, but PARS is a challenge for even the most patient of us.